AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31378318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol 2-g dose (therapeutic)
Number of subjects: 0
Study 31378318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol 4-g dose (supratherapeutic)
Number of subjects: 0
Study 31378318 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study 31378318 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400-mg oral dose
Number of subjects: 0
Study 28784498 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exposure to Brie, Gouda, and sharp Cheddar
Number of subjects: 0
Study 28784498 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exposure to Emmental, Gorgonzola, and Parmigiano‐Reggiano
Number of subjects: 0
Study 28784498 — intervention group
Group type: COMPARATOR
Intervention: Individual evaluation vs. social interaction
Number of subjects: 0
Study 26055774 — intervention group
Group type: EXPERIMENTAL
Intervention: Function Focused Care Intervention for the Cognitively Impaired (FFC‐CI)
Number of subjects: 96
Study 26055774 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 23052623 — intervention group
Group type: EXPERIMENTAL
Intervention: Starch-matrix beadlet (SMB, FloraGLO® Lutein 5 %)
Number of subjects: 48
Study 23052623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-linked alginate-matrix beadlet (AMB, Lyc-O-Lutein 20 %)
Number of subjects: 48
Study 22185023 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperuricemia (study group)
Number of subjects: 50
Study 19856512 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine regimen group A (1200 mg total over 3 days: 600 mg on day 1, 300 mg on days 2 and 3)
Number of subjects: 48
Study 19856512 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine regimen group B (1500 mg total over 3 days: 750 mg on day 1, 375 mg on days 2 and 3)
Number of subjects: 48
Study 16480348 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect-site steered propofol patient-controlled sedation (PCS)
Number of subjects: 40
Study 16480348 — intervention group
Group type: COMPARATOR
Intervention: Anaesthetist-administered propofol sedation
Number of subjects: 40
Study 16480348 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 15333431 — intervention group
Group type: EXPERIMENTAL
Intervention: EDLA (extended-duration local anesthetic) at concentrations of 6.25, 12.5, and 25 mg/mL
Number of subjects: 18
Study 15333431 — intervention group
Group type: COMPARATOR
Intervention: Aqueous bupivacaine (5.0 mg/mL)
Number of subjects: 18
Study 15333431 — intervention group
Group type: EXPERIMENTAL
Intervention: EDLA (extended-duration local anesthetic)
Number of subjects: 18
Study 11140434 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised fluticasone propionate 0.1 mg, twice daily for 4 days
Number of subjects: 21
Study 11140434 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised fluticasone propionate 1 mg, twice daily for 4 days
Number of subjects: 21
Study 11140434 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised fluticasone propionate 10 mg, twice daily for 4 days
Number of subjects: 21
Study 11140434 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily for 4 days
Number of subjects: 21
Study 9062598 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine (15 ml of 0.5% bupivacaine injected twice)
Number of subjects: 80
Study 9062598 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 ml of 0.9% saline solution injected twice)
Number of subjects: 80
Study 8282635 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal upright bicycle exercise
Number of subjects: 10
Study 8282635 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise (control) day
Number of subjects: 10
Study 3481331 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 or 400mg twice daily)
Number of subjects: 230
Study 3481331 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100mg twice daily)
Number of subjects: 230
Study 28784001 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance tocolysis with tablet nifedipine for 12 days or up to 34 weeks of gestation.
Number of subjects: 50
Study 28784001 — intervention group
Group type: COMPARATOR
Intervention: Control group (no maintenance tocolysis).
Number of subjects: 50
Study 27832747 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 128
Study 27832747 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 128
Study 25010527 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi intervention (16-week program, 1 hour sessions, 3 times a week)
Number of subjects: 6
Study 22067783 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone with ethacridine lactate
Number of subjects: 1245
Study 22067783 — intervention group
Group type: COMPARATOR
Intervention: Ethacridine lactate alone (Control)
Number of subjects: 1245
Study 20352148 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive counselling
Number of subjects: 135
Study 20352148 — intervention group
Group type: COMPARATOR
Intervention: Basic counselling
Number of subjects: 135
Study 18234355 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine or citalopram treatment for 1 year
Number of subjects: 65
Study 15681499 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 134
Study 15681499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 12859470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine 5%
Number of subjects: 25
Study 12859470 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-phenylcaine Forte (phenylephrine 0.5% and lidocaine 5%)
Number of subjects: 25
Study 12859470 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthesia using an atomiser
Number of subjects: 25
Study 12859470 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger diameter tubes
Number of subjects: 25
Study 10375948 — intervention group
Group type: EXPERIMENTAL
Intervention: Active sarcoidosis
Number of subjects: 188
Study 10375948 — intervention group
Group type: COMPARATOR
Intervention: Inactive sarcoidosis
Number of subjects: 188
Study 10375948 — intervention group
Group type: EXPERIMENTAL
Intervention: Active sarcoidosis treated with steroids
Number of subjects: 188
Study 10375948 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive sarcoidosis after corticotherapy
Number of subjects: 188
Study 10375948 — intervention group
Group type: EXPERIMENTAL
Intervention: Avian fanciers' lung exposed to antigen
Number of subjects: 188
Study 10375948 — intervention group
Group type: EXPERIMENTAL
Intervention: Avian fanciers' lung after a year interval in exposure to antigen
Number of subjects: 188
Study 10375948 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced idiopathic pulmonary fibrosis
Number of subjects: 188
Study 10375948 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate idiopathic pulmonary fibrosis
Number of subjects: 188
Study 10375948 — intervention group
Group type: COMPARATOR
Intervention: Healthy persons
Number of subjects: 188
Study 9049974 — intervention group
Group type: EXPERIMENTAL
Intervention: P53 gene mutations in CML blast crisis
Number of subjects: 27
Study 9049974 — intervention group
Group type: EXPERIMENTAL
Intervention: P53 gene point mutations
Number of subjects: 27
Study 9049974 — intervention group
Group type: EXPERIMENTAL
Intervention: P53 gene point mutation in extramedullary and bone marrow blast cells
Number of subjects: 27
Study 2058006 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool positive female patients
Number of subjects: 242
Study 2058006 — intervention group
Group type: COMPARATOR
Intervention: Stool negative female patients
Number of subjects: 242
Study 2058006 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool positive male patients
Number of subjects: 242
Study 2058006 — intervention group
Group type: COMPARATOR
Intervention: Stool negative male patients
Number of subjects: 242
Study 7076102 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin macrocrystals (100 mg every 12 hours for two days)
Number of subjects: 100
Study 7076102 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (160 mg and 800 mg respectively every 12 hours for two days)
Number of subjects: 100
Study 31625419 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exercise intervention (group A)
Number of subjects: 115
Study 31625419 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga exercise intervention (group C)
Number of subjects: 115
Study 31625419 — intervention group
Group type: COMPARATOR
Intervention: Pilates exercise intervention (group B)
Number of subjects: 115
Study 29481513 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 jaw surgery group (30 patients)
Number of subjects: 52
Study 29481513 — intervention group
Group type: COMPARATOR
Intervention: 2 jaw surgery group (22 patients)
Number of subjects: 52
Study 27595687 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA in combination with CTP
Number of subjects: 600
Study 27595687 — intervention group
Group type: COMPARATOR
Intervention: CCTA alone
Number of subjects: 600
Study 24333646 — intervention group
Group type: EXPERIMENTAL
Intervention: Escapable stressor condition
Number of subjects: 0
Study 24333646 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoked inescapable stressor condition
Number of subjects: 0
Study 24333646 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no stress exposure)
Number of subjects: 0
Study 22658147 — intervention group
Group type: EXPERIMENTAL
Intervention: ERN/LRPT + SIM
Number of subjects: 1398
Study 22658147 — intervention group
Group type: COMPARATOR
Intervention: SIM alone
Number of subjects: 1398
Study 22658147 — intervention group
Group type: COMPARATOR
Intervention: ERN/LRPT
Number of subjects: 1398
Study 22658147 — intervention group
Group type: EXPERIMENTAL
Intervention: ERN/LRPT + SIM for 12 weeks
Number of subjects: 1398
Study 19711257 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracisternal lysis with urokinase 120,000 IU/d for 48 hours followed by intrathecal nimodipine lavage for 7 days
Number of subjects: 20
Study 19711257 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 20
Study 17669143 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg
Number of subjects: 1584
Study 17669143 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 1584
Study 17669143 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine 20 mg
Number of subjects: 1584
Study 17669143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1584
Study 15498087 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide 60 microg three times daily (TID)
Number of subjects: 651
Study 15498087 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide 60 microg four times daily (QID)
Number of subjects: 651
Study 15498087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 651
Study 11450366 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroenterostomy
Number of subjects: 170
Study 11450366 — intervention group
Group type: EXPERIMENTAL
Intervention: Billroth II method
Number of subjects: 170
Study 11450366 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly selective vagotomy
Number of subjects: 170
Study 9572539 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (DS) 0.1% solution, 1 drop four times daily for 14 days
Number of subjects: 60
Study 9572539 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac tromethamine (KT) 0.5% solution, 1 drop four times daily for 14 days
Number of subjects: 60
Study 8113776 — intervention group
Group type: EXPERIMENTAL
Intervention: Day Hospital (DH) rehabilitation (27 hours of weekday treatment weekly)
Number of subjects: 111
Study 8113776 — intervention group
Group type: COMPARATOR
Intervention: Inpatient (INP) rehabilitation (48 hours of scheduled treatment weekly)
Number of subjects: 111
Study 8113776 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (DH and INP)
Number of subjects: 111
Study 8113776 — intervention group
Group type: EXPERIMENTAL
Intervention: Day Hospital (DH) rehabilitation
Number of subjects: 111
Study 2455331 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 22
Study 2455331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 2455331 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbachol (0.25 mg s.c.)
Number of subjects: 22
Study 2455331 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Carbachol (6 or 12 mg/day for 2 weeks)
Number of subjects: 22
Study 28994626 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISM (MCPAP for Moms plus implementation assistance)
Number of subjects: 30
Study 28994626 — intervention group
Group type: COMPARATOR
Intervention: MCPAP for Moms alone
Number of subjects: 30
Study 26692579 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR 300 mg/day
Number of subjects: 296
Study 26692579 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR 150 mg/day
Number of subjects: 296
Study 26692579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 24360928 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy alcohol use identified by routine screening (AUDIT-C)
Number of subjects: 63397
Study 23530755 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 200
Study 23530755 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 200
Study 21498906 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10mg/day)
Number of subjects: 302
Study 21498906 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (2.5mg/day)
Number of subjects: 302
Study 21498906 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (2mg/day)
Number of subjects: 302
Study 21498906 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 302
Study 18313597 — intervention group
Group type: EXPERIMENTAL
Intervention: SVC coil ON
Number of subjects: 113
Study 18313597 — intervention group
Group type: COMPARATOR
Intervention: SVC coil OFF
Number of subjects: 113
Study 18313597 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercoil distance (17-cm vs 21-cm)
Number of subjects: 113
Study 16325470 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose quinapril (10 mg/day)
Number of subjects: 0
Study 16325470 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0
Study 12603413 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade PIN group
Number of subjects: 387
Study 12603413 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 387
Study 11127501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold air provocation
Number of subjects: 0
Study 11127501 — intervention group
Group type: COMPARATOR
Intervention: Anesthetizing the nose
Number of subjects: 0
Study 11127501 — intervention group
Group type: COMPARATOR
Intervention: Inhaling an anti-cholinergic drug
Number of subjects: 0
Study 8861087 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (Livial, 2.5 mg daily)
Number of subjects: 129
Study 8861087 — intervention group
Group type: COMPARATOR
Intervention: Conjugated estrogens (Premarin, 0.625 mg daily) + Medrogestone (Colpron, 2 x 5 mg daily for 12 days each month)
Number of subjects: 129
Study 1298968 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide (100 mg/die)
Number of subjects: 30
Study 1298968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1298968 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide
Number of subjects: 30
Study 6723531 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage recombinant alpha 2 interferon (rIFN-alpha 2) administered as 50 X 10(6) E/m2 as 30-minute infusion on 5 consecutive days four-weekly
Number of subjects: 12
Study 6723531 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage recombinant alpha 2 interferon (rIFN-alpha 2) administered as 20 X 10(6) E/m2 subcutaneously thrice weekly
Number of subjects: 12
Study 31424491 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated coagulation factor VII (rFVIIa) 80 μg/kg intravenous
Number of subjects: 69
Study 31424491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 31424491 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated coagulation factor VII (rFVIIa)
Number of subjects: 69
Study 29439650 — intervention group
Group type: COMPARATOR
Intervention: ADPKD Outcomes Model (ADPKD-OM)
Number of subjects: 0
Study 29439650 — intervention group
Group type: COMPARATOR
Intervention: Baseline total kidney volume (TKV)
Number of subjects: 0
Study 27189282 — intervention group
Group type: EXPERIMENTAL
Intervention: COX‐2 inhibitor (COX‐2i)
Number of subjects: 69
Study 27189282 — intervention group
Group type: COMPARATOR
Intervention: Control (no COX‐2i)
Number of subjects: 69
Study 25227833 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine concomitant with nedaplatin
Number of subjects: 68
Study 25227833 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin concomitant with gemcitabine
Number of subjects: 68
Study 25227833 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expression of ERCC1
Number of subjects: 68
Study 25227833 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expression of RRM1
Number of subjects: 68
Study 25227833 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expression of LRP
Number of subjects: 68
Study 22307926 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paracetamol
Number of subjects: 132
Study 22307926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hyoscine butylbromide
Number of subjects: 132
Study 22307926 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of paracetamol + hyoscine butylbromide
Number of subjects: 132
Study 22307926 — intervention group
Group type: COMPARATOR
Intervention: Rescue analgesia
Number of subjects: 132
Study 19942435 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional gait analysis with a multi-segment foot model
Number of subjects: 18
Study 17852629 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% testosterone gel
Number of subjects: 32
Study 17852629 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 32
Study 16342345 — intervention group
Group type: EXPERIMENTAL
Intervention: VVIR pacing
Number of subjects: 102
Study 16342345 — intervention group
Group type: COMPARATOR
Intervention: DDDR pacing and antiarrhythmic drugs
Number of subjects: 102
Study 11979157 — intervention group
Group type: COMPARATOR
Intervention: Light multidisciplinary treatment program
Number of subjects: 195
Study 11979157 — intervention group
Group type: COMPARATOR
Intervention: Extensive multidisciplinary treatment program
Number of subjects: 195
Study 11979157 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 195
Study 11979157 — intervention group
Group type: COMPARATOR
Intervention: Light multidisciplinary treatment
Number of subjects: 195
Study 9536408 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraffin wax plus Acetulan in cetyl alcohol
Number of subjects: 10
Study 9536408 — intervention group
Group type: EXPERIMENTAL
Intervention: Beeswax plus Acetulan in cetyl alcohol
Number of subjects: 10
Study 9536408 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraffin wax plus beeswax in cetyl alcohol
Number of subjects: 10
Study 9536408 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetulan in cetyl alcohol
Number of subjects: 10
Study 9536408 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraffin wax in cetyl alcohol
Number of subjects: 10
Study 8907133 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan 0.25 mg
Number of subjects: 24
Study 8907133 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan 0.5 mg
Number of subjects: 24
Study 8907133 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan 2 mg
Number of subjects: 24
Study 8907133 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan 4 mg
Number of subjects: 24
Study 8907133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1696310 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+ leukemia
Number of subjects: 795
Study 1696310 — intervention group
Group type: COMPARATOR
Intervention: CD34- leukemia
Number of subjects: 795
Study 356707 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pentazocine (0.9 mg/kg)
Number of subjects: 200
Study 356707 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine (1 mg/kg)
Number of subjects: 200
Study 356707 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.2 mg/kg)
Number of subjects: 200
Study 356707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 29878266 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (WHE)
Number of subjects: 10
Study 29878266 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lactalbumin-enriched whey protein (LAC)
Number of subjects: 10
Study 29878266 — intervention group
Group type: COMPARATOR
Intervention: Casein (CAS)
Number of subjects: 10
Study 28174052 — intervention group
Group type: EXPERIMENTAL
Intervention: Expedited transfer to a cardiac arrest centre (CAC) for goal-directed therapy including access to immediate reperfusion
Number of subjects: 40
Study 28174052 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care involving delivery to the geographically closest hospital
Number of subjects: 40
Study 26194186 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation plus perioperative ECF chemotherapy
Number of subjects: 752
Study 26194186 — intervention group
Group type: COMPARATOR
Intervention: Perioperative ECF chemotherapy
Number of subjects: 752
Study 23585314 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram 1 (bolus of 80 U/Kg/h and initial infusion rate of 17 U/Kg/h)
Number of subjects: 140
Study 23585314 — intervention group
Group type: COMPARATOR
Intervention: Nomogram 2 (bolus of 60 U/Kg, maximum of 4000 U, and initial infusion rate of 12 U/Kg/h, maximum of 900 U/h)
Number of subjects: 140
Study 20061402 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus interferon (IFN)‐alpha2a
Number of subjects: 649
Study 20061402 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus interferon (IFN)‐alpha2a
Number of subjects: 649